INDRAPRASTHA MEDICAL CORP.LTD.

Indraprastha Medical Corporation Ltd has announced the closure of its trading window for all designated persons, including promoters, directors, KMPs, and employees, from July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. During this period, no transactions involving the company's securities will be permitted for insiders and their immediate relatives. The exact date of the board meeting to approve these results will be communicated later.

Indraprastha Medical Corporation Ltd approved audited financial results for the quarter/year ended March 31, 2026, and recommended a dividend of 40% (₹4 per equity share) for FY26, subject to shareholder approval at the AGM. The board meeting concluded at 4:35 p.m. on May 12, 2026. Auditors have issued an unmodified opinion on the financial results.

Indraprastha Medical Corporation Ltd. has scheduled a Board of Directors meeting for Tuesday, May 12, 2026. The agenda includes considering and approving the audited financial results for the quarter and year ended March 31, 2026. Furthermore, the Board will also discuss and potentially recommend a dividend on the company's equity shares for the financial year 2025-26. This announcement is made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indraprastha Medical Corporation Ltd has announced that Mr. Vinayak Chatterjee (DIN 00008933) has completed his second term of five consecutive years as an Independent Director on the company's Board of Directors. He will cease to be a Director and Member/Chairperson of the respective committees of the board at the end of the day on 31st March, 2026. The decision follows the regulations set by the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indraprastha Medical Corporation Ltd has announced the closure of its trading window from 1st April, 2026, till 48 hours after the announcement of the audited financial results for the quarter and year ending on 31st March, 2026. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code of Conduct for Prevention of Insider Trading. During the closure period, all directors, Designated Employees, Insiders and their immediate relatives are prohibited from entering into any transaction involving the securities of the Company. The trading window will reopen 48 hours after the announcement of the audited financial results. The date of the Board Meeting to consider and approve the audited financial results will be intimated in due course.

The board of Indraprastha Medical Corporation Ltd approved the appointment of Mr. Harsh Pati Singhania as an Independent Director and the re-appointment of Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli as Independent Directors for a period of 5 consecutive years each. The appointments are subject to the approval of the shareholders of the company. The company also released its un-audited financial results for the quarter and nine months ended 31st December 2025.

Indraprastha Medical Corporation Ltd. has approved the un-audited financial results for the quarter and nine months ended 31st December 2025. The company has also appointed Mr. Harsh Pati Singhania as an Independent Director and re-appointed Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli as Independent Directors, subject to shareholder's approval. The Board of Directors has considered and approved these items at its meeting held on 34 February 2026.

Indraprastha Medical Corporation Ltd has announced that its Board of Directors will meet on February 34, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended 31st December, 2025. This is in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indraprastha Medical Corporation Ltd has announced that the trading window will be closed from 1st January, 2026 till 48 hours after the announcement/declaration of unaudited financial results for the quarter and nine months ending on 31st December, 2025. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code of Conduct for Prevention of Insider Trading. During the closure, directors, Designated Employees, Insiders and their immediate relatives are prohibited from entering into any transaction involving the securities of the Company. The trading window will open 48 hours after the announcement/declaration of the unaudited financial results.

Indraprastha Medical Corporation Ltd. has announced its unaudited financial results for the quarter ended 30th September 2025. The company's profit before tax stands at Rs. 134.62 crore, a 5.40% increase compared to the same period last year. The total income for the quarter is Rs. 388.40 crore, with revenue from operations at Rs. 381.03 crore and other income at Rs. 7.37 crore. The total expenses for the quarter amounted to Rs. 322.09 crore, with cost of materials consumed at Rs. 7.37 crore, employee benefits expense at Rs. 6.05 crore, and finance costs at Rs. 56.23 crore. The company's net profit for the quarter is Rs. 65.45 crore, and the earnings per share (EPS) is Rs. 11.01. The total assets of the company stand at Rs. 954.11 crore, and the total liabilities are Rs. 596.68 crore.